Shanghai Rightongene Biotechnology Co. Ltd. Class A

As of June 30, 2026, Shanghai Rightongene Biotechnology Co. Ltd. Class A carries a market capitalization of 1.15B, placing it among publicly traded companies globally. Its enterprise value stands at 917.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Rightongene Biotechnology Co. Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Shanghai Rightongene Biotechnology Co. Ltd. Class A has 55.86M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 6.79, and the price-to-book ratio stands at 1.39.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 917.08M versus a market cap of 1.15B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shanghai Rightongene Biotechnology Co. Ltd. Class A maintains a current ratio of 17.65, meaning it holds 17.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Shanghai Rightongene Biotechnology Co. Ltd. Class A posted a negative return on equity (ROE) of -6.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.19, reflecting losses generated across the asset base. The company generates approximately 476,945.32 in revenue per employee across its workforce of 352.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.97 indicates how many times Shanghai Rightongene Biotechnology Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shanghai Rightongene Biotechnology Co. Ltd. Class A recorded 19.02M in income tax expense. The company reported a pretax loss of -49.71M and -56.90M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Shanghai Rightongene Biotechnology Co. Ltd. Class A's stock has declined approximately 21.90% over the past 52 weeks. The 50-day moving average sits at 24.15, while the 200-day moving average is 26.16.

Over the twelve months ended June 30, 2026, Shanghai Rightongene Biotechnology Co. Ltd. Class A generated 168.00M in revenue and converted that into -56.90M in net income, yielding earnings per share of -1.24. EBITDA reached -48.47M, while operating income came in at -3.92M.

As of June 30, 2026, Shanghai Rightongene Biotechnology Co. Ltd. Class A holds 234.66M in cash and equivalents against 1.73M in total debt, resulting in a net debt position of -137.65M. Total book value stands at 832.53M, with working capital of 404.85M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Rightongene Biotechnology Co. Ltd. Class A posted a gross margin of 77.87, reflecting its pricing power and cost economics. The operating margin of -2.34 and net profit margin of -33.87 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Shanghai Rightongene Biotechnology Co. Ltd. Class A paid dividends of 0.17 per share. The dividend payout ratio of -11.67 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.09, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shanghai Rightongene Biotechnology Co. Ltd. Class A shareholders.

As of June 30, 2026, Shanghai Rightongene Biotechnology Co. Ltd. Class A has an Altman Z-Score of 21.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.